This week in Singapore, the Obama administration has a different focus -- providing "more" for the MPAA and big pharma lobby. That should change, before this huge trade deal is concluded.
Read Whole Story
While the GOP and Democratic conventions highlight the differences between the parties, there are some bipartisan issues -- and one of the biggest is taking care of corporate interests.
Biologics are an exciting new world of medicine. But the EMA's new guidelines should put patient safety first by requiring biosimilars to be held to the same safety and standards as the original drug.
As a matter of common sense, the FDA's process for biosimilars shouldn't sacrifice patient safety.
Pelosi made a choice about the lifesaving biologic drugs I took when I was in chemotherapy that will cost many fellow breast cancer survivors everything they own, and quite possibly their lives.
Get top stories and blog posts emailed to me each day. Newsletters may offer personalized content or advertisements. Learn more.